

CPA of Application No. 09/455,543
Attorney Docket No. 045112-0045

dependent protein kinase, and growth factor receptor inhibitors, said composition having a pharmaceutically effective amount of the compounds selected on a basis of a therapeutic treatment for soft tissue cancer.

5. The composition of claim 1, wherein the soft tissue cancer is breast cancer.
6. The composition of claim 1, wherein eugenol is selected on a basis of therapeutic treatment for soft tissue cancer.
7. The composition of claim 1, wherein thymol is selected on a basis of therapeutic treatment for soft tissue cancer.
8. The composition of claim 1, wherein isoeugenol is selected on a basis of therapeutic treatment for soft tissue cancer.
9. The composition of claim 1, wherein benzyl alcohol is selected on a basis of therapeutic treatment for soft tissue cancer.
10. The composition of claim 1, wherein carvacrol is selected on a basis of therapeutic treatment for soft tissue cancer.
11. The composition of claim 1, wherein cinnamic alcohol is selected on a basis of therapeutic treatment for soft tissue cancer.
12. The composition of claim 1, wherein cinnamic aldehyde is selected on a basis of therapeutic treatment for soft tissue cancer.
13. The composition of claim 1, wherein citronellal is selected on a basis of therapeutic treatment for soft tissue cancer.

3
101
14. The composition of claim 1, wherein trans-anethole is selected on a basis of therapeutic treatment for soft tissue cancer.

4
16. The composition of claim 1, wherein α -terpineol is selected on a basis of therapeutic treatment for soft tissue cancer.

Please add new Claims 17-28 as follow.

5
17. A composition for the treatment of cancerous medical conditions, said composition comprising a cAMP inducer and a compound selected from a group consisting of α -terpineol, benzyl alcohol, carvacrol, eugenol, isoeugenol, cinnamic aldehyde, thyme oil, thymol, trans-anethole, said composition having a pharmaceutically effective amount of the compound selected on a basis of a therapeutic treatment for soft tissue cancer.

18. The composition of claim 17, wherein the cAMP inducer is forskolin.

19. The composition of claim 18, wherein eugenol is selected on a basis of therapeutic treatment for soft tissue cancer.

20. The composition of claim 18, wherein cinnamic aldehyde is selected on a basis of therapeutic treatment for soft tissue cancer.

21. A composition for the treatment of cancerous medical conditions, said composition comprising a c-Src kinase inhibitor and a compound selected from a group consisting of thymol and eugenol, said composition having a pharmaceutically effective amount of the compound selected on a basis of a therapeutic treatment for soft tissue cancer.

22. The composition of claim 21, wherein geldanamycin is the c-Src kinase inhibitor.

23. The composition of claim 22, wherein eugenol is selected on a basis of therapeutic treatment for soft tissue cancer.